40th week of 2011 patent applcation highlights part 46 |
Patent application number | Title | Published |
20110243847 | IMAGING DIAGNOSTICS BY COMBINING CONTRAST AGENTS - The present invention relates to the use of a combination of several contrast agents having different properties with respect to imaging representation. | 2011-10-06 |
20110243848 | STAR POLYMERS, METHODS OF PREPARATION THEREOF, AND USES THEREOF - A composition of matter comprising an amphiphilic star polymer, the star polymer comprising a crosslinked microgel core and 6 or more independent polymer arms covalently linked to the core, the 6 or more arms each comprising a hydrophilic polymer chain segment and a hydrophobic polymer chain segment; wherein each individual metal selected from the group consisting of beryllium, magnesium, calcium, strontium, barium, radium, aluminum, gallium, indium, thallium, germanium, tin, lead, arsenic, antimony, bismuth, tellurium, polonium, and metals of Groups 3 to 12 of the Periodic Table has a concentration in the star polymer of greater than or equal to 0 parts per million and less than or equal to 100 parts per million. | 2011-10-06 |
20110243849 | HEME-BINDING PHOTOACTIVE POLYPEPTIDES AND METHODS OF USE THEREOF - The present disclosure provides photoactive polypeptides. A subject photoactive polypeptide is useful in a variety of applications, which are also provided. | 2011-10-06 |
20110243850 | PROBE FOR A BIOLOGICAL SPECIMEN AND LABELLING METHOD AND SCREENING METHOD USING THE PROBE - Provided is a novel probe for a biological specimen for labelling by itself and clearly visualizing one of a specific cell and a specific cell organ in a living body, the probe having excellent spectral characteristics and exhibiting excellent storage stability. The probe for a biological specimen contains, as an active agent, at least one kind of compound represented by a general formula (I). | 2011-10-06 |
20110243851 | GLUCOSE-PEG CONJUGATES FOR REDUCING GLUCOSE TRANSPORT INTO A CELL - There is provided a glucose-PEG conjugate comprising a PEG moiety conjugated to a linear glucose moiety at the C1 position of the glucose moiety. The glucose-PEG conjugate may be used to reduce glucose transport into a cell and may be used to treat a proliferative disorder. | 2011-10-06 |
20110243852 | METHOD FOR THE PRODUCTION OF LABELLED SCAFFOLDS, COMPRISING AT LEAST ONE REACTIVE FLUORINATED SURFACTANT, AND SCAFFOLD PRODUCED THEREWITH - The present invention is related to scaffolds for tissue engineering and organ engineering. More particularly, the present invention is related to a method for the production of a labelled scaffold for tissue and/or organ engineering comprising a reactive fluorinated surfactant, which serve as imaging label for medical imaging means, like CT, MRI, PET, scintigraphy and/or ultrasound imaging and the like. | 2011-10-06 |
20110243853 | MODELS OF ERYTHROPOIESIS - Non human animal models are provided for diseases involving erythroid function, particularly myeloproliferative disease. The models are useful for testing and screening of biologically active agents that affect erythropoiesis, and erythroid function. In the animal models of the invention, a hematopoietic stem or progenitor cell (HSC) population that has been genetically altered by the introduction of a mutant JAK2 coding sequence is transplanted into an immunocompromised, xenogeneic, non-human recipient. The recipient animal is engrafted with the cell population at a high frequency, and develops a myeloproliferative disorder characterized by polycythemia. | 2011-10-06 |
20110243854 | Methods and systems for identifying modulators of longevity - Methods of treating disorders such as neurofibromatosis-1 are provided, including methods in which catalytic antioxidants such as metalloporphyrins are administered. Methods of regulating longevity, and methods and systems for screening for modulators of aging or longevity, are also provided. In addition, related transgenic animals are described. | 2011-10-06 |
20110243855 | METHOD AND IMAGING MEDIUM FOR USE IN THE METHOD - The invention relates to a method of | 2011-10-06 |
20110243856 | Permeable Mixtures, Methods and Compositions for the Skin - Topical mixtures with ranges of permeability which promote dermal healing, wound stage arrest, skin cooling, and patient comfort through pH adjustment, therapeutic ingredient carriage, water and oxygen delivery, with superior aesthetics and ease of cleaning features. | 2011-10-06 |
20110243857 | SMART CONTRAST AGENTS FOR MRI IMAGING - A contrast agent for MRI imaging includes: (a) one cyclodextrin, whose truncated-cone-shaped structure defines a central axis, a first and a second openings along the axis, (b) one paramagnetic element, located on the cyclodextrin axis, outside the structure and proximate to the first opening, (c) one or several coordination ligand(s) of the paramagnetic element which coordinate(s) the paramagnetic element, (d) one arm covalently bound to the cyclodextrin, proximate to the second opening, which is able to form an inclusion complex with the cyclodextrin. | 2011-10-06 |
20110243858 | HYDROXYLATED CONTRAST ENHANCEMENT AGENTS AND IMAGING METHOD - A method of diagnostic imaging is disclosed comprising administering a medical formulation to a subject, the formulation comprising a contrast enhancement agent having structure I and salts thereof | 2011-10-06 |
20110243859 | ENCAPSULATING SYSTEM FOR CEST IMAGING WITH CHELATE Q GREATER THAN OR EQUAL TO 2 - The present invention relates to the use of a CEST contrast agent in a method of CEST imaging, wherein the contrast agent is a composition comprising an encapsulating system ES encapsulating at least one CEST agent, wherein the at least one CEST agent is constituted of a monomeric chelate of a chelate of q≧2 type, or of a multimer of monomeric chelates of q≧2 type, and wherein said chelate is free inside the encapsulating system. | 2011-10-06 |
20110243860 | ORAL CARE COMPOSITIONS - Oral care compositions that are stable, pourable and swishable suspension containing suspending polymer(s). Optional further components include abrasives, surfactants, flavorings, colorings, anti-plaque agents, anti-tartar agents, agents for sensitive teeth, fluoride ion sources and sweeteners. | 2011-10-06 |
20110243861 | ORAL CARE COMPOSITIONS - The present invention relates generally to oral care compositions, and more specifically to oral care compositions suitable for cleaning the oral cavity. Methods of use are also disclosed. | 2011-10-06 |
20110243862 | COSMETIC OR PHARMACEUTICAL COMPOSITION, IN PARTICULAR INTENDED FOR CARE OR FOR MAKEUP - A composition includes from 40 to 80% by weight of at least one non-volatile hydrogenated polyalkylene oil; from 10 to 50% by weight of at least one tertiary-amide-terminated polyamide (ATPA) polymer; and further at least one fatty acid ester having at least one free hydroxyl group, and preferably a hydroxystearate ester. The composition is translucid. | 2011-10-06 |
20110243863 | Cosmetic And/Or Pharmaceutical Formulations - The invention relates to cosmetic and/or pharmaceutical formulations, comprising n-octyl-n-octanoate. | 2011-10-06 |
20110243864 | DISPERSION OF SOFT POLYMER PARTICLES, COSMETIC COMPOSITION COMPRISING IT AND COSMETIC TREATMENT METHOD - The present invention relates to a dispersion of polymer particles in a liquid carbon-based medium, the said particles having a flexible polymeric core and being surface-stabilized with a block stabilizing polymer comprising at least one block that is soluble in the said carbon-based medium and at least one block that is insoluble in the said carbon-based medium. | 2011-10-06 |
20110243865 | MELANIN PRODUCTION INHIBITOR - Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor comprises a compound represented by general formula (1) (excluding clotrimazole), and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent, wherein at least one of A1, A2 and A3 is selected from the aryl group and the aromatic heterocyclic group, the total number of carbon atoms contained in A1, A2 and A3 is 6 to 50 and, when at least two of A1, A2 and A3 represent the aryl groups or the aromatic heterocyclic groups, the adjacent two aryl or aromatic heterocyclic groups may be bound to each other via an alkyl chain or an alkenyl chain to form a ring; m represents an integer of 0 to 2; X represents a hetero atom, a hydrogen atom, or a carbon atom; R1 and R2 are independently selected from a hydrogen atom and an oxo group, wherein when one of R1 and R2 is an oxo group, the other is not present; and R3 is selected from a hydrogen atom, and a C | 2011-10-06 |
20110243866 | COSMETIC COMPOSITION FOR MAKE-UP AND PROCESS FOR MAKING SAME - A process for the preparation of a make-up cosmetic comprising: a) dryly preparing a powder mixture consisting of talc, mica, silica, colorants, pearls and binders, wherein colorants are present in percentages from 1 to 99%, pearls are present in percentages from 1 to 99%, and the binder are present in percentages from 1 to 99%; b) sieving the mixture obtained; c) wetting the mixture obtained at step b) with one or more oil-based compounds selected from the group consisting of: a mineral or vegetable oil, a fatty alcohol, an ester, a silicone oil, a triglyceride and a wax, in percentages ranging from 1% to 50%; d) adding the mixture obtained in step c) to an aqueous solution, suspension, dispersion or emulsion in percentages from 1 to 99%; e) depositing the mixture obtained in step d), manually, mechanically or with a press, on or in a support; and f) baking the mixture obtained in step e) in an oven at a temperature ranging from 5° C. to 150° C. and under a pressure ranging from 10 mm of mercury to 1520 mm of mercury. | 2011-10-06 |
20110243867 | COSMETIC COMPOSITIONS CONTAINING POLYPROPYLSILSESQUIOXANE, A VOLATILE SOLVENT, BORON NITRIDE, AND SILICA - Disclosed are cosmetic compositions containing a polypropylsilsesquioxane, a volatile solvent, boron nitride, and silica. Also disclosed are methods for making the cosmetic compositions and applying them to keratinous tissue such as skin in order to enhance its appearance. | 2011-10-06 |
20110243868 | ACETALS AS PERFUMING INGREDIENTS - The present invention relates to the field of perfumery. More particularly, it concerns some acetal derivatives of 3-methyl citral of formula (I) wherein the dotted lines indicate the presence of a single or double bond; R | 2011-10-06 |
20110243869 | WAX-FREE COSMETIC COMPOSITIONS CONTAINING A LATEX AND A FILLER - Disclosed are cosmetic compositions containing from about 10% to about 60% of a latex, and from about 10% to about 60% of a filler; wherein the ratio of latex to filler is from about 3.5:1 about 1:1.5, and the composition is free of wax. Also disclosed are methods for making the cosmetic compositions, wherein the entire process is carried out a temperature of about 30° C. or less. Further disclosed are methods of making up or enhancing the appearance of a keratinous substance comprising applying the cosmetic composition to the keratinous substance. | 2011-10-06 |
20110243870 | CONDITIONING SHAMPOO COMPRISING AN AQEUOUS CONDITIONING GEL PHASE IN THE FORM OF VESICLES - Conditioning shampoo composition comprising a cleaning phase and an aqueous conditioning gel phase comprising a cationic surfactant having from 16 to 30 carbons and multi-lamellar vesicles. | 2011-10-06 |
20110243871 | ORGANOSILICONES - The present application relates to organosilicones and compositions such as consumer products comprising such organosilicones, as well as processes for making and using such organosilicones and such compositions. Such compositions comprising such organosilicones are easier to formulate, and provide more economical and superior care benefits when compared to current silicone containing compositions. | 2011-10-06 |
20110243872 | CARBOHYDRATE TREATMENT FOR FRAGRANCED ARTICLES - A carbohydrate treatment composition composing modified starches, preservatives, an incorporation factor and water The treatment composition may also preferably comprise a fragrance The composition may be used to coat a litter material substrate and also may be used in a fragrance delivery composition for personal care products A method of coating a litter material using a carbohydrate material is also presented. | 2011-10-06 |
20110243873 | Rheology modifier polymer - A polymer includes (a) one or more first monomeric units, each independently comprising at least one bicycloheptyl-polyether, bicycloheptenyl-polyether or branched (C | 2011-10-06 |
20110243874 | CARE POLYMERS - The present application relates to care agents, for example care polymers, and compositions such as consumer products comprising such care agents, as well as processes for making and using such care agents and such compositions. The performance of the care polymers that Applicants teach, can be further increased by following the emulsification teaching of the present specification and/or combining such care polymers with silicone materials. | 2011-10-06 |
20110243875 | CARE POLYMERS - The present application relates to care agents, for example care polymers, and compositions such as consumer products comprising such care agents, as well as processes for making and using such care agents and such compositions. The performance of the care polymers that Applicants teach, can be further increased by following the emulsification teaching of the present specification and/or combining such care polymers with silicone materials. | 2011-10-06 |
20110243876 | ORGANOSILICONES - The present application relates to organosilicones and compositions such as consumer products comprising such organosilicones, as well as processes for making and using such organosilicones and such compositions. Such compositions comprising such organosilicones are easier to formulate, and provide more economical and superior care benefits when compared to current silicone containing compositions. | 2011-10-06 |
20110243877 | Embalming composition and method - A method of retarding the decomposition of human remains comprises embalming the remains with an aqueous solution of chlorine dioxide. | 2011-10-06 |
20110243878 | ORGANOSILICONES - The present application relates to organosilicones and compositions such as consumer products comprising such organosilicones, as well as processes for making and using such organosilicones and such compositions. Such compositions comprising such organosilicones are easier to formulate, and provide more economical and superior care benefits when compared to current silicone containing compositions. | 2011-10-06 |
20110243879 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. | 2011-10-06 |
20110243880 | MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF - A polynucleotide delivery vehicle comprising a modified polymer is provided herein, the modified polymer having the following formula: | 2011-10-06 |
20110243881 | BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM - A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): A | 2011-10-06 |
20110243882 | ANTIBACTERIAL POLYMER EMULSION AND COATING COMPOSITION - An aqueous antibacterial polymer emulsion and coating compositions are provided. The aqueous antibacterial polymer emulsion comprising a polymer A, an oxidant and a metal complexed with a copolymer B comprising heterocyclic containing monomers; wherein the metal is selected from copper, silver, gold, tin, zinc and combinations thereof; and wherein the emulsion is heat stable. The coating compositions made therefrom provide persistent, broad spectrum antibacterial activity without discoloration problem upon exposure to heat and/or sun light. | 2011-10-06 |
20110243883 | POLYMERIC BIOLUBRICANTS FOR MEDICAL USE - The present invention provides branched polymers which can be used as lubricants or shock absorbers in vivo. For example, the inventive polymers can be used as viscosupplements, viscoelastics, tissue space fillers, and/or anti-adhesive agents. Also provided are pharmaceutical compositions comprising the inventive polymers and methods of using them including, for example, in the treatment of arthritic and sport-injured knee joints; in reconstruction or cosmetic procedures, intervertebral disc repair, treatment of vocal cord problems, treatment of urinary incontinence, and prevention of adhesion formation following abdominal or gynecological surgery. | 2011-10-06 |
20110243884 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES - The invention relates to a biodegradable polymer comprising a plurality of releasable bioactive moieties, the releasable bioactive moieties being pendant from and covalently bonded to the biodegradable polymer backbone, wherein the biodegradable polymer backbone is formed from monomeric units that are each coupled via a biodegradable moiety, and wherein the bioactive moieties are capable of being released at a rate equal to or faster than the rate of biodegradation of the polymer backbone. | 2011-10-06 |
20110243885 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function - This invention relates to methods of using genotyping to select patients for treatment with compounds capable of elevating ketone body concentrations in amounts effective to treat reduced neuronal metabolism associated with reduced neuronal metabolism, for example Alzheimer's disease. | 2011-10-06 |
20110243886 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS - Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 2011-10-06 |
20110243887 | IL-7 FUSION PROTEINS - The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7). | 2011-10-06 |
20110243888 | IL-29 MUTANTS AND USES THEREOF - The present invention relates to truncated IL-29 mutant molecules and methods of using same. The truncated IL-29 molecules can be used to treat viral infections, such as hepatitis C, autoimmune disorders and various types of cancer. | 2011-10-06 |
20110243890 | Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus - The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus. | 2011-10-06 |
20110243891 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE - The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar | 2011-10-06 |
20110243892 | Y-SHAPE BRANCHED HYDROPHILIC POLYMER DERIVATIVES, THEIR PREPARATION METHODS, CONJUGATES OF THE DERIVATIVES AND DRUG MOLECULES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE CONJUGATES - The present invention relates to Y-shape branched PEG derivatives of formulae (I) to (IV). The present invention also relates to conjugates of these Y-shape derivatives and drug molecules, pharmaceutical compositions comprising those conjugates. | 2011-10-06 |
20110243893 | MARKERS FOR DETERMINATION OF PATIENT RESPONSIVENESS - Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica. | 2011-10-06 |
20110243894 | METHODS OF TREATING HEPATITIS C VIRUS INFECTION - The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from HCV infection. Also provided are methods of treating liver steatosis and liver fibrosis. | 2011-10-06 |
20110243895 | Generation of patient-specific differentiated cell types by epigenetic induction - Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated human cancer cell. Methods to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment of a human patient by administering the patient-specific cell line to the patient. | 2011-10-06 |
20110243896 | ANTI-VIRAL PROTECTION WITH VIRUSES CONTAINING DEFECTIVE GENOME SEGMENTS - The invention relates to virology and the prevention and/or treatment of viral infection and disease in animals, including birds and humans. The invention relates to the field of antiviral treatments. The invention further relates to methods of stimulating innate immunity and natural interferon production in humans or animals and in component parts of humans or animals, including cells and tissues. The invention also relates to the field of defective interfering (DI) viruses, including cloned DI viruses. | 2011-10-06 |
20110243897 | MODIFICATION OF NUCLEIC ACID VECTORS WITH POLYMERS COMPRISING CHARGED QUATERNARY AMINO GROUPS - The present invention provides a polymer modified nucleic acid vector in which the nucleic acid vector is covalently linked to a polymer, which polymer comprises one or more positively charged quaternary amino groups. | 2011-10-06 |
20110243898 | SOMATIC CELL-DERIVED PLURIPOTENT CELLS AND METHODS OF USE THEREFOR - Provided are methods for producing a reprogrammed fibroblast. The methods can include growing a plurality of fibroblasts in monolayer culture to confluency; and disrupting the monolayer culture to place at least a fraction of the plurality of fibroblasts into suspension culture under conditions sufficient to form one or more embryoid body-like spheres, wherein the one or more embryoid body-like spheres comprise one or more reprogrammed fibroblasts that express one or more markers not expressed by a fibroblast growing in the monolayer culture prior to the disrupting step. Also provided are reprogrammed fibroblasts produced by the disclosed methods, formulations that include reprogrammed fibroblasts, and methods for treating an injury to a tissue in a subject by administering to a subject in need thereof a composition of reprogrammed fibroblast cells in a pharmaceutically acceptable carrier. | 2011-10-06 |
20110243899 | Wnt Signaling Inhibitor Comprising Insulin-Like Growth Factor-Binding Protein - Provided is a novel soluble factor that modulates morphogenesis and cell proliferation, such as cardiac development and/or cardiomyocyte differentiation. Specifically provided are: an inhibitor of Wnt signalling, comprising an insulin-like growth-factor-binding protein (IGFBP), the protein being binding to a Wnt receptor, and/or a polynucleotide encoding the protein; a medicament for prevention and/or treatment of a disease due to enhanced Wnt signalling, comprising the inhibitor of Wnt signalling, and a medicament for induction of cardiomyocyte differentiation; and a method for prevention and/or treatment of a disease due to enhanced Wnt signalling and a method of inducing cardiomyocyte differentiation, the methods each comprising using the inhibitor of Wnt signalling, and a cardiomyocyte, which is obtained by the method of inducing cardiomyocyte differentiation, and a use thereof. | 2011-10-06 |
20110243900 | SOFT TISSUE AND BONE AUGMENTATION AND BULKING UTILIZING MUSCLE-DERIVED PROGENITOR CELLS, COMPOSITIONS AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction. | 2011-10-06 |
20110243901 | Compositions and Methods for the Treatment of Lysosomal Storage Disorders - The present invention relates to methods for providing lysosomal enzymes to a subject by administering stem cells, preferably Multipotent Adult Progenitor Cells (MAPCs). The invention further relates to methods for treating lysosomal storage disorders by administering stem cells. | 2011-10-06 |
20110243902 | METHOD FOR TREATING OR PREVENTING A PANCREATIC DYSFUNCTION - The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1 | 2011-10-06 |
20110243903 | USE OF A ROCK INHIBITOR TO SUSTAIN PRIMARY HUMAN KERATINOCYTES IN A PROLIFERATIVE STATE - Disclosed herein is the finding that treatment with a ROCK inhibitor increases proliferation and induces immortalization of primary keratinocytes. Accordingly, provided is a method of immortalizing primary keratinocytes by exposure to a ROCK inhibitor. Also provided are immortalized primary keratinocytes produced by the described method, as well as organotypic tissue equivalents and cell cultures comprising the immortalized primary keratinocytes. Furthermore, ROCK inhibitor-treated cells show a greatly increased ability to support viral DNA replication of both “low risk” and “high risk” HPV genomes, indicating that ROCK inhibitors will be useful for studying the life cycles of a wide range of HPVs. | 2011-10-06 |
20110243904 | RNA INTERFERENCE TARGET FOR TREATING AIDS - The present invention relates to RNA interference target sequence targeting HIV for the treatment of AIDS. Based on the target sequence, recombinant expression vectors, packaging vectors and cells were constructed, which express a siRNA and/or a miRNA and/or a ribozyme and/or an antisense oligonucleotide targeting HIV. Also provided is the use of the recombinant expression vectors, packaging vectors and recombinant cells in the manufacture of a medicament for the treatment of AIDS. | 2011-10-06 |
20110243905 | STRAIN OF HIGHLY MOSQUITOCIDAL BACILLUS - A new strain of | 2011-10-06 |
20110243906 | STRAIN OF HIGHLY MOSQUITOCIDAL BACILLUS - A new strain of | 2011-10-06 |
20110243907 | COSMETIC AND NUTRITIONAL ALPHA-OMEGA COMPLEX COMPOSITION - The present invention is an alpha omega complex composition for use in cosmetic and nutritional products and formulations for a user that contains coenzyme Q10, selenium sulfide and n-acetyl cysteine. Specific cosmetic and nutritional products and formulations include face cream, night cream, eye cream, lip cream, shampoos, conditioners, hand cream, body cream, daily dietary supplements, hair regeneration cream, anti-acne cream, anti-radiation cream, skin serum, eye-lash regeneration lotion and exfoliate products and formulations. One embodiment of the alpha omega complex composition would include 2.5% by volume NAC, 0.1% by volume Q10 and 0.05% by volume SeS | 2011-10-06 |
20110243908 | Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 2011-10-06 |
20110243909 | Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 2011-10-06 |
20110243910 | MAMMALIAN RNA DEPENDENT RNA POLYMERASE - The invention provides compositions comprising a TERT-RMRP or TERT-RNA complex and methods of treating subjects with genetic diseases in which gene silencing is either increased by administering the compositions of the invention or decreased by administering an inhibitor of the RNA-dependent RNA polymerase (RdRP) activity of these compositions. Moreover, the invention provides methods of screening for agonists and antagonists of RdRP activity and TERT-RMRP complex formation. Finally, the invention provides a method of identifying a RNA molecule that forms a complex with a TERT polypeptide and has RdRP activity. | 2011-10-06 |
20110243911 | USE OF A COMPOUND CAPABLE OF REDUCING THE URIC ACID LEVEL FOR THE PREVENTION AND/OR THE TREATMENT OF LUNG INFLAMMATION AND FIBROSIS - The present invention is directed to the use of a compound capable of reducing the uric acid level in a mammal for the prevention and/or the treatment of IL-1β driven lung pathology, particularly to treat lung inflammation such as chronic fibrosis, COPD and interstitial fibrosis and other IL-1β driven lung pathologies including those of autoimmune origin. Preferred compounds capable of reducing the uric acid level are selected from the group consisting of xanthine oxidase inhibitors, such as allopurinol, recombinant enzyme uricase and uricosuric compound capable of enhancing uric acid excretion, such as probenecid. The invention further relates to a method for identifying in vitro whether a patient presents an IL-1β driven lung pathology or is at risk to develop an IL-1β driven lung pathology, or for the screening of a compound for treating an IL-1β driven lung pathology. | 2011-10-06 |
20110243912 | Growth Factor Binding Constructs Materials and Methods - The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided. | 2011-10-06 |
20110243913 | Biomaterial Compositions and Methods of Use - The invention relates to biomaterial compositions and methods for promoting bone regeneration and hemostasis. The invention also relates to compositions and methods for promoting wound healing. In various embodiments, the compositions comprise crosslinkable collagen molecules and calcium phosphate suitable for bone regeneration. In various embodiments, the compositions comprise crosslinkable collagen molecules suitable for promoting hemostasis or wound healing; or suitable as tissue sealants. In some embodiments, the compositions contain additional agents, including biological agents. | 2011-10-06 |
20110243914 | SHIGA TOXIN B-SUBUNIT AS A VECTOR FOR TUMOR DIAGNOSIS AND DRUG DELIVERY TO GB3 EXPRESSING TUMORS - The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb | 2011-10-06 |
20110243915 | ANTIMICROBIAL AGENTS - The present invention relates to endolysin variants comprising an endolysin to which a peptide stretch with membrane or LPS disrupting activity is fused. Moreover, the present invention relates to nucleic acid molecules encoding said modified endolysin variant, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to a method for producing said endolysin variant. Further, the present invention relates to said modified endolysin variant for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said endolysin variant as a diagnostic means in medicinal, food or feed or environmental diagnostic. Finally, the present invention relates to a pharmaceutical composition comprising said modified endolysin variant | 2011-10-06 |
20110243916 | MODIFIED ENDOLYSIN PLY511 - The present invention relates to polypeptides with a changed amino acid sequence on at least one amino acid position compared to the amino acid sequence according to SEQ ID NO: 1. The present invention further relates to the nucleotide sequences encoding the polypeptide, vectors, comprising the nucleotide sequences and host cells for expression of the polypeptide. The present invention further relates to the use of the polypeptides as a human, veterinary medical or diagnostic substance, in food, in cosmetics, as disinfectant or in the environmental field. | 2011-10-06 |
20110243917 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF ABSENCE SEIZURES COMPRISING PKC AGONIST AS AN EFFECTIVE INGREDIENT - The present invention relates to a composition comprising PKC agonist as an active ingredient. More precisely, the present inventors confirmed that absence seizure specific SWD was reduced by administrating PKC agonist into an animal model. Therefore, the composition of the present invention comprising PKC agonist as an active ingredient can be effectively used for the prevention and treatment of absence seizure and for the production of health improving functional food. | 2011-10-06 |
20110243918 | TOPICAL MEDICATION FOR THE TREATMENT OF HEMORRHOIDS AND METHOD OF USE - A natural gel/ointment for the treatment of hemorrhoids. Bromelain is one primary active ingredient in the gel/ointment. A second active ingredient such as Hamamelis Virginiana (Witch Hazel) may be combined with the Bromelain. Secondary ingredients include alcohol, de-ionized water, Butylene Glycol, PEG-40 Hydrogenated Castor Oil, Hydroxyethylcellulose, Eucalyptus Globulus Oil, Aloe Barbadensis Leaf Extract, Chamomilla Rectutita Flower Extract, Camellia Sinensis Leaf Extract, Avena Sativa Kernel Flour, Benzophenone-4, Disodium EDTA, Sodium Citrate, Sodium Hydroxide, Citric Acid, Caprylyl Glycol, Chlorphenesin and Methylisothiazolinone. Based on case studies the gel/ointment outperforms other hemorrhoid medications. | 2011-10-06 |
20110243919 | Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 2011-10-06 |
20110243920 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 2011-10-06 |
20110243921 | PREVENTION AND TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS - Disclosed herein, in certain embodiments, are methods and compositions for the prevention and treatment of autoimmune disease. Further disclosed herein, in certain embodiments, are methods for the prevention and treatment of cutaneous lupus erythematosus. Additionally disclosed herein, in certain embodiments, are compositions for the prevention and treatment of cutaneous lupus erythematosus. | 2011-10-06 |
20110243922 | Genetic Alterations Associated with Type I Diabetes and Methods of Use Thereof for Diagnosis and Treatment - Compositions and methods for the detection and treatment of T1D are provided. | 2011-10-06 |
20110243923 | ORGANIC COMPOUNDS - The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7, 25-dihydroxycholesterol) (“7,25DHC”) and/or cholest-5-ene-3b, 7b-diol (7-hydroxycholesterol) (“7HC”). The modulator maybe a small chemical molecule, antibody or other therapeutic protein. Methods of medical treatment and methods of identifying modulators are also described. | 2011-10-06 |
20110243924 | NOVEL METHODS - The invention provides methods of inhalation treatment of a respiratory disease or condition in a patient in need to such treatment without producing in said patient systemic antimuscarinic effects, comprising administering to said patient an effective amount of aclidinium. | 2011-10-06 |
20110243925 | Gene Expression Profiles Being Predictive for the Response of Tumors to Pharmaceutically Effective Compounds - The present invention relates to a method for providing a gene expression profile being predictive for the specific response of an individual tumor to a pharmaceutically effective compound, the use thereof, a microarray wherein the nucleotide sequences attached to the substrate consist of nucleotide sequences corresponding to the predictive genes of said gene expression profile, and a diagnostic kit containing said microarray. | 2011-10-06 |
20110243926 | ANTI-P-SELECTIN ANTIBODIES AND METHODS OF USING THE SAME TO TREAT INFLAMMATORY DISEASES - The invention features antibodies, e.g., chimeric and humanized antibodies, that recognize (i.e., bind) P-selectin. The P-selectin antibodies prevent P-selectin from binding to its cognate receptor. The P-selectin antibodies can be used to treat inflammatory and thrombotic conditions, e.g., sickle cell disease, pain crisis associated with sickle cell disease, deep vein thrombosis, asthma, rheumatoid arthritis, psoriasis, and ischemia reperfusion injury in a patient in need thereof. | 2011-10-06 |
20110243927 | METHODS OF INHIBITING TUMOR GROWTH USING BETA 5 INTEGRIN ANTAGONISTS - The present invention relates to methods for treating cancer by administering to a mammalian subject a therapeutically effective amount of a selective β | 2011-10-06 |
20110243928 | CHIMERIC AND HUMANISED MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-13 - The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed. | 2011-10-06 |
20110243929 | ANTI-ICOS ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE - The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder. | 2011-10-06 |
20110243930 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 2011-10-06 |
20110243931 | COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES - The present application is directed to the combination therapy of a type I and a type II anti-CD20 antibody for the treatment of cancer, especially of CD20 expressing cancer. | 2011-10-06 |
20110243932 | ANTI-CD40 ANTIBODIES - The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same. | 2011-10-06 |
20110243933 | Perifosine and Capecitabine as a Combined Treatment for Cancer - Treatment regimens comprising co-treatment of cancer with perifosine and capecitabine are disclosed herein, as well as pharmaceutical compositions and unit dosage forms thereof formulated to be suitable for use in said treatment regimens. | 2011-10-06 |
20110243934 | EPHA3 ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of multiple myeloma. | 2011-10-06 |
20110243935 | Compositions and Methods for Immunotherapy - The invention relates to immunotherapeutic compounds, compositions that include such compounds, and methods of using the compounds, for example, to treat an individual having, at risk for, or previously treated for a cancer. | 2011-10-06 |
20110243936 | TNFalpha-NEUTRALIZING ANTIBODIES - The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications. | 2011-10-06 |
20110243937 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER - The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-10-06 |
20110243938 | Methods to Reduce B-Helper T Cells to Treat Autoimmune Diseases - The present invention includes compositions and methods for the treatment of autoimmune diseases by administering to a subject having an autoimmune disorder an effective amount of a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one IL-12 inhibitor, e.g., a blocking anti-IL-12 antibody or fragment thereof. | 2011-10-06 |
20110243939 | MODIFICATION OF NUCLEIC ACID VECTORS WITH POLYMERS COMPRISING CHARGED QUATERNARY AMINO GROUPS - The present invention provides a polymer modified nucleic acid vector in which the nucleic acid vector is covalently linked to a polymer, which polymer comprises one or more positively charged quaternary amino groups, wherein the nucleic acid vector is a micro-organism selected from the group consisting of a virus, a bacteria or a bacteriophage, a fungus, a spore, a eukaryotic cell nucleus or other micro-organism fragment or a component containing genetic information, and wherein (a) the polymer and/or the linkages between it and the nucleic acid vector are hydrolytically, reducibly or enzymatically degradable; and/or (b) wherein each of the positively charged quaternary amino groups is linked to the polymer backbone via one or more degradable or biodegradable linkages. | 2011-10-06 |
20110243940 | BICYCLIC PYRANONE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Bicyclic Pyranone Derivatives, their compositions and uses for treating or preventing a metabolic disorder, dyslipidemia, a cardiovascular disease, a neurological disorder, a hematological disease, cancer, inflammation, a respiratory disease, a gastroenterological disease, diabetes, a diabetic complication, obesity, an obesity-related disorder or non-alcoholic fatty liver disease. Formula (I). Y is —C— when an optional and additional bond is present and Y is —CH— when an optional and additional bond is not present; Z is —O—, —NH— or —N(alkyl)- when the optional and additional bond between Y and Z Is absent, and Z Is —N— when the optional and additional bond between Y and Z is present; R | 2011-10-06 |
20110243941 | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same - The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC. | 2011-10-06 |
20110243942 | RELAXIN-FUSION PROTEINS WITH EXTENDED IN VIVO HALF-LIVES - Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion proteins may include a linker portion or other sections as well. Suitable fusion proteins are also those predicted to have the same effect as human relaxin in vivo, based, for example, on structural modeling. The fusion protein is useful in the treatment of a number of diseases and conditions, including heart disease, vascular disease, wound healing, fibrosis, fibromyalgia, and promoting angiogenesis. | 2011-10-06 |
20110243943 | TREATMENT USING RELAXIN-FUSION PROTEINS WITH EXTENDED IN VIVO HALF-LIVES - Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion proteins may include a linker portion or other sections as well. Suitable fusion proteins are also those predicted to have the same effect as human relaxin in vivo, based, for example, on structural modeling. The fusion protein is useful in the treatment of a number of diseases and conditions, including heart disease, vascular disease, wound healing, fibrosis, fibromyalgia, and promoting angiogenesis. | 2011-10-06 |
20110243944 | Fusion Protein Inhibiting Osteoclast Formation, Preparation Method and Medicine Compositions Thereof - The present invention provides a coding gene having the nucleic acid sequence shown as SEQ ID NO:1 and the fusion protein RIG (SEQ ID NO:2) that inhibits osteoclast formation. The present invention also provides the preparation method for the fusion protein RIG as well as synthetic oligo-nucleotide primers, plasmids and host cells used in the method and a medicine having the above fusion protein RIG as active ingredient. The fusion protein RIG in present invention is derived from humanized immunoglobulin and RANKL with a flexible hinge region. RIG can cross link the cell surface receptor RANK and Fcγ 1 to induce a cytosolic inhibitory signal leading to the inhibition of osteoclast formation. The fusion protein RIG in present invention can play an essential role in treating osteoporosis and bone resorption diseases caused by tumor metastasis. | 2011-10-06 |
20110243945 | Anti-Inflammatory Agents - This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions. | 2011-10-06 |
20110243946 | Remedies for pemphigus containing anti Fas ligand antibodies - The present invention refers to the use of FasL antagonists, e.g. of humanized antibodies directed against human Fas ligands (also named CD95L or Apo1L and hereinafter abbreviated as FasL) for the prevention and/or treatment of skin diseases associated with keratinocytes acantholysis, particularly for the prevention and/or treatment of pemphigus. | 2011-10-06 |
20110243947 | ANTIBODIES AGAINST CSF-1R - The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin. | 2011-10-06 |